Tumor Volume Changes After Stereotactic, Hypofractionated and Conventional Radiotherapy in Paragangliomas of Head and Neck

Overview

Journal Cancer Med

Specialty Oncology

Date 2024 Sep 13

PMID 39268626

Authors

Pawel J Polanowski

Agnieszka R Kotecka-Blicharz

Andrzej Tukiendorf

Natalia J Amrogowicz

Aleksandra M Nasiek

Agnieszka Pietruszka

Katarzyna M Polanowska

Krzysztof A Skladowski

Affiliations

Soon will be listed here.

Abstract

Background: The aim of this study is comparison the effectiveness of stereotactic, hypofractionated and conventional radiotherapy assessed by the tumor volume changes of paraganglioma located in the head and neck region concerning fractional and total doses.

Methods: We analyzed 76 patients after radiotherapy due to paraganglioma who were assigned to 3 groups considering fractional (≤2 Gy, 3-5.5 Gy, ≥6 Gy) and total (≤20 Gy, 21-40 Gy, >40 Gy) doses. The volumes of irradiated tumors were measured and compared based on diagnostic images performed before and after the treatment.

Results: The mean tumor volume after the treatment with the lowest fractional dose (≤2 Gy) was decreased by 14.4 cm. In patients treated with higher fractional doses (>2 Gy), the mean tumor volumes decreased by less than 1 cm for hypofractionated and stereotactic radiotherapy. 15.9 cm reduction of the mean tumor volume after the treatment with the highest RT total dose (>40 Gy) was stated. In patients treated with total doses ≤20 Gy and 21-40 Gy, the mean tumor volume was stable and reduced by 1.15 cm, respectively. The analysis demonstrates a statistically significant (p < 0.05) treatment advantage in patients after the lowest fractional and highest total doses.

Conclusion: The reduction of the tumor's volume was reported after conventional and unconventional radiotherapy. The most significant depletion of the paraganglioma volume was noted after a factional dose ≤2 Gy and a total dose >40 Gy.

References

Angelousi A, Kassi E, Zografos G, Kaltsas G . Metastatic pheochromocytoma and paraganglioma. Eur J Clin Invest. 2015; 45(9):986-97. DOI: 10.1111/eci.12495. View

Suarez C, Rodrigo J, Bodeker C, Llorente J, Silver C, Jansen J . Jugular and vagal paragangliomas: Systematic study of management with surgery and radiotherapy. Head Neck. 2012; 35(8):1195-204. DOI: 10.1002/hed.22976. View

Marchetti M, Pinzi V, Tramacere I, Bianchi L, Ghielmetti F, Fariselli L . Radiosurgery for Paragangliomas of the Head and Neck: Another Step for the Validation of a Treatment Paradigm. World Neurosurg. 2016; 98:281-287. DOI: 10.1016/j.wneu.2016.10.132. View

Kahn L . Vagal body tumor (nonchromaffin paraganglioma, chemodectoma, and carotid body-like tumor) with cervical node metastasis and familial association: ultrastructural study and review. Cancer. 1976; 38(6):2367-77. DOI: 10.1002/1097-0142(197612)38:6<2367::aid-cncr2820380625>3.0.co;2-3. View

Suarez C, Rodrigo J, Mendenhall W, Hamoir M, Silver C, Gregoire V . Carotid body paragangliomas: a systematic study on management with surgery and radiotherapy. Eur Arch Otorhinolaryngol. 2013; 271(1):23-34. DOI: 10.1007/s00405-013-2384-5. View

Bracigliano A, Marretta A, Guerrera L, Simioli R, Clemente O, Granata V . The Management of Phaeochromocytomas and Paragangliomas in the Era of Precision Medicine: Where Are We Now? Evidence-Based Systemic Treatment Options and Future Cluster Oriented Perspectives. Pharmaceuticals (Basel). 2024; 17(3). PMC: 10975789. DOI: 10.3390/ph17030354. View

Jackson C . Glomus tympanicum and glomus jugulare tumors. Otolaryngol Clin North Am. 2001; 34(5):941-70, vii. DOI: 10.1016/s0030-6665(05)70356-x. View

Chetty R . Familial paraganglioma syndromes. J Clin Pathol. 2010; 63(6):488-91. DOI: 10.1136/jcp.2010.076257. View

Brink I, Hoegerle S, Klisch J, Bley T . Imaging of pheochromocytoma and paraganglioma. Fam Cancer. 2005; 4(1):61-8. DOI: 10.1007/s10689-004-2155-y. View

10.

Tosun I, Atalar B, Sahin B, Gungor G, Aydin G, Yapici B . Robotic radiosurgery of head and neck paragangliomas: a single institution experience. Asia Pac J Clin Oncol. 2017; 14(2):e3-e7. DOI: 10.1111/ajco.12695. View

11.

Bikhazi P, Roeder E, Attaie A, Lalwani A . Familial paragangliomas: the emerging impact of molecular genetics on evaluation and management. Am J Otol. 1999; 20(5):639-43. View

12.

Smith J, Harvey R, Darr O, Prince M, Bradford C, Wolf G . Head and neck paragangliomas: A two-decade institutional experience and algorithm for management. Laryngoscope Investig Otolaryngol. 2018; 2(6):380-389. PMC: 5743157. DOI: 10.1002/lio2.122. View

13.

Williams M, Tischler A . Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Paragangliomas. Head Neck Pathol. 2017; 11(1):88-95. PMC: 5340727. DOI: 10.1007/s12105-017-0786-1. View

14.

Hu K, Persky M . Treatment of Head and Neck Paragangliomas. Cancer Control. 2016; 23(3):228-41. DOI: 10.1177/107327481602300306. View

15.

Weissmann T, Lettmaier S, Roesch J, Mengling V, Bert C, Iro H . Paragangliomas of the Head and Neck: Local Control and Functional Outcome Following Fractionated Stereotactic Radiotherapy. Am J Clin Oncol. 2019; 42(11):818-823. DOI: 10.1097/COC.0000000000000614. View

16.

Sandow L, Thawani R, Kim M, Heinrich M . Paraganglioma of the Head and Neck: A Review. Endocr Pract. 2022; 29(2):141-147. PMC: 9979593. DOI: 10.1016/j.eprac.2022.10.002. View

17.

Myssiorek D . Head and neck paragangliomas: an overview. Otolaryngol Clin North Am. 2001; 34(5):829-36, v. DOI: 10.1016/s0030-6665(05)70349-2. View

18.

Harrison L, Corbridge R . Active surveillance management of head and neck paragangliomas: case series and review of the literature. J Laryngol Otol. 2017; 131(7):580-584. DOI: 10.1017/S0022215117000809. View

19.

Cass N, Schopper M, Lubin J, Fishbein L, Gubbels S . The Changing Paradigm of Head and Neck Paragangliomas: What Every Otolaryngologist Needs to Know. Ann Otol Rhinol Laryngol. 2020; 129(11):1135-1143. DOI: 10.1177/0003489420931540. View

20.

van der Mey A, Frijns J, Cornelisse C, Brons E, van Dulken H, Terpstra H . Does intervention improve the natural course of glomus tumors? A series of 108 patients seen in a 32-year period. Ann Otol Rhinol Laryngol. 1992; 101(8):635-42. DOI: 10.1177/000348949210100802. View